arrow
A

Alan Lau

AstraZeneca
H指数:37
被引数:9,978

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC

I期研究:评估ceralasertib(一种ATR激酶抑制剂)联合durvalumab治疗复发或转移性NSCLC或HNSCC患者的疗效。

2026-03-310
OAAI
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer

KEAP1和STK11/LKB1突变增强KRAS突变非小细胞肺癌对ATR抑制的易感性

2025-07-100
OAAI
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

ATR抑制剂ceralasertib通过调节肿瘤微环境来增强癌症检查点免疫治疗

2024-02-248
OAAI
Immunomodulatory effects of the ATR inhibitor ceralasertib in a window of opportunity biomarker trial in patients with head and neck squamous cell carcinoma
2023-04-140
PRE
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

确定对WEE1或ATR抑制有反应的乳腺癌和卵巢癌模型的分子定义子集,克服PARP抑制剂耐药性

2022-08-0327
OAAI
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib

ATR抑制剂AZD6738 (Ceralasertib) 作为单一疗法以及与化疗和PARP抑制剂Olaparib联合使用具有抗肿瘤活性

2022-03-1566
OAAI
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging
2022-01-1024
PRE
Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
2021-07-2260
OAAI